Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FATENASDAQ:FGENNASDAQ:GLSINYSE:IKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFATEFate Therapeutics$1.42+4.4%$1.09$0.66▼$5.92$162.74M2.322.21 million shs1.90 million shsFGENFibroGen$0.31+1.3%$0.30$0.18▼$1.53$30.83M0.862.02 million shs509,953 shsGLSIGreenwich LifeSciences$9.34-2.2%$9.62$8.06▼$18.75$124.86M1.6946,272 shs36,444 shsIKTInhibikase Therapeutics$1.98-2.5%$2.01$1.12▼$4.20$147.20M0.94235,331 shs93,068 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFATEFate Therapeutics+4.62%+11.48%+3.82%+50.26%-62.94%FGENFibroGen+2.55%-6.28%-9.63%-23.53%-75.50%GLSIGreenwich LifeSciences-0.93%-4.31%-4.40%-20.08%-31.74%IKTInhibikase Therapeutics-0.98%+14.69%-9.78%-8.97%+9.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFATEFate Therapeutics4.2823 of 5 stars4.12.00.04.72.11.70.6FGENFibroGen4.0306 of 5 stars3.32.00.04.71.43.30.6GLSIGreenwich LifeSciences2.1019 of 5 stars3.50.00.00.03.33.30.0IKTInhibikase Therapeutics1.2452 of 5 stars3.32.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFATEFate Therapeutics 2.22Hold$4.14191.75% UpsideFGENFibroGen 2.50Moderate Buy$10.003,177.61% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00317.56% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50228.28% UpsideCurrent Analyst Ratings BreakdownLatest FGEN, FATE, IKT, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/18/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/6/2025FATEFate TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$5.00 ➝ $3.003/6/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.003/6/2025FATEFate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFATEFate Therapeutics$13.34M12.20N/AN/A$3.74 per share0.38FGENFibroGen$7.00M4.41N/AN/A($1.87) per share-0.16GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/AIKTInhibikase Therapeutics$260K566.14N/AN/A$1.78 per share1.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFATEFate Therapeutics-$160.93M-$1.49N/AN/AN/A-1,325.43%-45.88%-33.95%8/12/2025 (Estimated)FGENFibroGen-$284.23M-$0.10N/AN/AN/A-67.66%N/A-36.17%8/5/2025 (Estimated)GLSIGreenwich LifeSciences-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ALatest FGEN, FATE, IKT, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/12/2025Q1 2025FGENFibroGen$0.03-$0.16-$0.19$0.05$2.00 million$2.70 million4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/17/2025Q4 2024FGENFibroGen-$0.08-$0.08N/A$0.18$24.91 million$3.14 million3/5/2025Q4 2024FATEFate Therapeutics-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFATEFate TherapeuticsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFATEFate TherapeuticsN/A8.298.29FGENFibroGenN/A1.281.16GLSIGreenwich LifeSciencesN/A6.916.91IKTInhibikase TherapeuticsN/A0.850.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFATEFate Therapeutics97.54%FGENFibroGen72.71%GLSIGreenwich LifeSciences4.16%IKTInhibikase Therapeutics3.81%Insider OwnershipCompanyInsider OwnershipFATEFate Therapeutics5.51%FGENFibroGen3.07%GLSIGreenwich LifeSciences51.67%IKTInhibikase Therapeutics7.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableFGENFibroGen570101.04 million98.78 millionOptionableGLSIGreenwich LifeSciences313.37 million6.35 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableFGEN, FATE, IKT, and GLSI HeadlinesRecent News About These CompaniesInhibikase Therapeutics Reports Q1 2025 Financial ResultsMay 23, 2025 | tipranks.comSoleus Capital Management L.P. Takes $20.56 Million Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 21, 2025 | marketbeat.comStonepine Capital Management LLC Makes New $3.68 Million Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 20, 2025 | marketbeat.comInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14, 2025 | finance.yahoo.comInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14, 2025 | globenewswire.comFormer Inhibikase leader launches new biotech for midstage Parkinson’s assetMay 12, 2025 | fiercebiotech.comFairmount Funds Management LLC Purchases Shares of 6,125,000 Inhibikase Therapeutics, Inc. (NYSE:IKT)May 10, 2025 | marketbeat.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 6.22%May 9, 2025 | aaii.comBlackstone Inc. Makes New Investment in Inhibikase Therapeutics, Inc. (NYSE:IKT)May 8, 2025 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)May 5, 2025 | prnewswire.comInhibikase Therapeutics: A Hold With Uncertain Prospects In PAHMay 2, 2025 | seekingalpha.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 5.30%April 17, 2025 | aaii.comInhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-marketApril 16, 2025 | nasdaq.comInhibikase Therapeutics Advances PAH Treatment with New LeadershipApril 14, 2025 | tipranks.comInhibikase Therapeutics announces appointment of McIntyre as CFOApril 14, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial OfficerApril 14, 2025 | globenewswire.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 14.13%April 8, 2025 | aaii.comHedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term lossesApril 4, 2025 | finance.yahoo.comInhibikase Therapeutics (IKT) Receives a Hold from H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityMarch 27, 2025 | globenewswire.comInhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowMarch 5, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, FATE, IKT, and GLSI Company DescriptionsFate Therapeutics NASDAQ:FATE$1.42 +0.06 (+4.41%) As of 04:00 PM EasternFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.FibroGen NASDAQ:FGEN$0.31 +0.00 (+1.26%) As of 04:00 PM EasternFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Greenwich LifeSciences NASDAQ:GLSI$9.34 -0.21 (-2.20%) As of 04:00 PM EasternGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Inhibikase Therapeutics NYSE:IKT$1.98 -0.05 (-2.46%) As of 04:00 PM EasternInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
